Forma Therapeutics is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of novel therapeutics to transform the lives of patients with rare hematologic diseases and cancers. Its R&D engine combines deep biology insight, chemistry expertise and clinical development capabilities to create drug candidates with differentiated mechanisms of action focused on indications with high unmet need. Its work has generated a broad proprietary portfolio of programs with the potential to provide profound patient benefit.
Company profile
Ticker
FMTX
Exchange
Website
CEO
Frank D. Lee
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Forma Therapeutics Holdings LLC, Forma Therapeutics Holdings, Inc.,
SEC CIK
Corporate docs
Subsidiaries
Forma Securities Corporation • Forma Therapeutics, Inc. ...
IRS number
371657129
FMTX stock data
Latest filings (excl ownership)
15-12G
Securities registration termination
24 Oct 22
EFFECT
Notice of effectiveness
18 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Oct 22
POS AM
Prospectus update (post-effective amendment)
14 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Oct 22
S-8 POS
Registration of securities for employees (post-effective amendment)
14 Oct 22
SC 14D9/A
Tender offer solicitation (amended)
14 Oct 22
SC TO-T/A
Third party tender offer statement (amended)
14 Oct 22
25-NSE
Exchange delisting
14 Oct 22
Transcripts
FMTX
Earnings call transcript
2022 Q2
5 Aug 22
FMTX
Earnings call transcript
2022 Q1
6 May 22
FMTX
Earnings call transcript
2021 Q4
1 Mar 22
FMTX
Earnings call transcript
2021 Q3
12 Nov 21
FMTX
Earnings call transcript
2021 Q2
13 Aug 21
FMTX
Earnings call transcript
2021 Q1
14 May 21
FMTX
Earnings call transcript
2020 Q4
30 Mar 21
Latest ownership filings
Financial summary
Quarter (USD) | Jun 22 | Mar 22 | Dec 21 | Sep 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 77.29 mm | 77.29 mm | 77.29 mm | 77.29 mm | 77.29 mm | 77.29 mm |
Cash burn (monthly) | (no burn) | (no burn) | 17.67 mm | 15.93 mm | 14.92 mm | 14.17 mm |
Cash used (since last report) | n/a | n/a | 386.05 mm | 348.05 mm | 326.07 mm | 309.71 mm |
Cash remaining | n/a | n/a | -308.76 mm | -270.76 mm | -248.78 mm | -232.42 mm |
Runway (months of cash) | n/a | n/a | -17.5 | -17.0 | -16.7 | -16.4 |
Institutional ownership, Q1 2023
9.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 3 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 113.71 mm |
Total shares | 4.50 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Lilly Ventures Fund I | 2.40 mm | $83.90 mm |
Novartis Bioventures | 1.76 mm | $24.99 mm |
LLY Lilly(Eli) & Co | 339.19 k | $4.82 mm |